Skip to content
  • ABOUT US
    • What Do We Do?
    • Why Are We Better?
    • Senior Management
    • How To Contact Us
  • TRANSACTIONS
    • Chemical Transactions
    • Life Science Transactions
  • BROADCASTS & PUBLICATIONS
    • Our Broadcasts
    • Our Publications
    • Our Analyses
      • Chemical Industry Analyses
      • Pharmaceutical Industry Analyses
      • Biotechnology Industry Analyses
      • Medical Device Industry Analyses
  • CONFERENCES
    • Chemical Conferences
    • Life Science Conferences
  • INDUSTRY PORTALS
    • ChemicalIndustry.com
    • PharmaIndustry.com
    • MedicalDeviceIndustry.com
  • YOUNG & PARTNERS FORUM
  • ABOUT US
    • What Do We Do?
    • Why Are We Better?
    • Senior Management
    • How To Contact Us
  • TRANSACTIONS
    • Chemical Transactions
    • Life Science Transactions
  • BROADCASTS & PUBLICATIONS
    • Our Broadcasts
    • Our Publications
    • Our Analyses
      • Chemical Industry Analyses
      • Pharmaceutical Industry Analyses
      • Biotechnology Industry Analyses
      • Medical Device Industry Analyses
  • CONFERENCES
    • Chemical Conferences
    • Life Science Conferences
  • INDUSTRY PORTALS
    • ChemicalIndustry.com
    • PharmaIndustry.com
    • MedicalDeviceIndustry.com
  • YOUNG & PARTNERS FORUM

Our Publications

  • Our Broadcasts
  • Our Publications
  • Our Analyses
Jonathan Choi2023-03-14T19:28:18+00:00

Biopharma M&A: Year in Review, Ripples Ahead (Pharmaceutical Executive, March 2023)

Young & Partners shares analysis of the global disruptions and uncertainties that have affected Biopharma M&A and the outlook for 2023.

Jonathan Choi2023-02-08T02:20:40+00:00

Debt Financing to be difficult in 2023 (ICIS Chemical Business February 3 – February 9, 2023)

Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed Stock Prices and Financings and the outlook for 2023.

Jonathan Choi2023-01-26T15:10:20+00:00

Young & Partners Pharma and Biotech M&A Review and Outlook (January 20, 2023)

Proprietary data and analysis of 2022 and the current outlook.

Jonathan Choi2023-01-26T15:10:48+00:00

Young & Partners Chemical M&A Review and Outlook (January 17, 2023)

Proprietary data and analysis of 2022 and the current outlook.

Jonathan Choi2023-01-26T15:01:39+00:00

Disruptions to hit M&A, financing (ICIS Chemical Business December 2 – December 8, 2022)

Young & Partners shows that global disruptions and uncertainties are suppressing M&A, Stock Prices and Financings.

digitalstudios2022-08-28T14:56:04+00:00

Chemical M&A trends shift down (ICIS Chemical Business August 26 – September 1, 2022)

Young & Partners shows that global disruptions and uncertainties are suppressing M&A, Stock Prices and Financings.

digitalstudios2022-08-12T18:23:33+00:00

Pharm Exec: Navigating the Financial Meltdown for Biopharma (Young & Partners article – August 2022 issue)

A review of pharma and biotech equity market, IPO, and M&A trends and disruptions through the first half of 2022 and the implications for the future.

Devin Maraj2022-04-12T16:14:36+00:00

Structural Changes and Disruptions (ICIS Chemical Business April 8 – April 21 2022)

Young & Partners covers the changes the chemical industry is facing now and will face in the future

Devin Maraj2022-03-12T02:24:09+00:00

Pharm Exec: Biopharma in 2021 Big Gains, Volatile Values (Young & Partners article – March 2022)

Young & Partners View of the Strategic, M&A and Financial trends in 2021 and outlook

Devin Maraj2022-03-01T15:13:27+00:00

Pharm Exec: China Invests in Building Biotech (Young & Partners comments – January 2022)

Young & Partners comments on what to expect from China in this article

12Next

DISCLAIMER

© YOUNG & PARTNERS LLC   |   535 Fifth Avenue, 4th Floor, New York, New York 10017 | 212-682-5555

Page load link
Go to Top